Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-MMO tirzepatide cardiovascular outcomes study in adults with obesity or overweight
NL-OMON60534Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Tirzepatide once weekly with Placebo once weekly (2 arms). Primary endpoint: Time to first occurrence of any component event of composite. Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON60534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60534.